BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today ...

Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen ...

BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Matthew Allard is a multi-award-winning, ACS accredited freelance Director of Photography with over 30 years' of experience working in more than 50 countries around the world. He is the Editor of ...

BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

Sam Slutsky has given his Buy rating due to a combination of factors including the promising clinical developments and the financial stability of Pyxis Oncology. The firm’s current cash reserves ...

Investing.com - Pyxis Oncology (NASDAQ: PYXS) reported fourth quarter EPS of $-1.04, $0.11 worse than the analyst estimate of $-0.93. Revenue for the quarter came in at $0.00... Pyxis Oncology ...